The National Eczema Association for Science and Education (NEASE) is the representative and the advocate for 20 million people in the United States who have eczema problems, and I write on their behalf. Our major concern is the well-being of the patients we represent. The detailed comments by Stern1 on the decision-making process used by the external pediatric committee in advising the US Food and Drug Administration (FDA) regarding topical calcineurin inhibitors raise several issues that are useful to place into public discussion.
Cooper K. National Eczema Association and Topical Calcineurin Inhibitor Labeling. Arch Dermatol. 2007;143(4):543-551. doi:10.1001/archderm.143.4.546-a